THE SOLUTION:

KETAMINE FOR PAIN MANAGEMENT

The FDA first approved ketamine in 1970 for anesthesia. It was added to the World Health Organization’s Model List of Essential Medicines in 1985. In 2019 a pure S-enantiomer variant of ketamine was approved for intranasal delivery in treatment of Major Depression. Ketamine is a novel and powerfully effective pain reliever, with research establishing efficacy across a broad range of pain types (e.g., neuropathic, inflammatory, nociceptive). Effects upon pain are synergistic and diverse.3,4 They are proven equal to or better than strong opioid and opiate medications, including methadone, meperidine, fentanyl and morphine.5,6,7,8,9,10,11 Ketamine's distinct pharmacodynamic properties allow reliable reduction of opioid use in pain management.16,17,18,19 Indeed, pain status improves with ketamine over time rather than worsening,20,21 likely due to reversal of hyperalgesic forces that often transform acute pain into chronic pain conditions. Increased pain signaling commonly results from opioid medications, a disturbing byproduct of current pain management techniques.22 Ketamine's potential is notable, with dozens of studies demonstrating efficacy in pain conditions and safety data established through decades of available data on patients ages 8 to 93. 

BB106

SUBCUTANEOUS DELIVERY OF KETAMINE

While ketamine has remarkable therapeutic potential, its utility is limited by its short half-life and low-bioavailability when taken orally or intranasally.  Bexson’s subcutaneous delivery solution with a wearable and minimally invasive patch pump allows of continuous release at therapeutically relevant doses.  The company’s proprietary formulation, BB106, has the solubility and chemical properties that allow for subcutaneous delivery.

Pain relief is achieved at low doses compared to depression

Existing research has established substantial pain relief with ketamine dosing that is substantially lower than those often used to treat depression.  Lower dosing translates to fewer side effects and increased safety in population-wide assessment.   

 

Key Opinion Leaders in pain management confirm the need for Bexson's technology

Ketamine is already used to great effect by pain physicians, but delivery limitations hamper broader solutions. Key opinion leaders in pain management express notable enthusiasm and interest in Bexson's new low-dose subcutaneous ketamine delivery platform.  

 

The Opioid Public Health Emergency in pain management demands answers

The misery and death associated with the national opioid crisis mandates safer treatments with effect size large enough to replace opioids. No other medication can off this except ketamine. Physicians need new treatment options, the FDA is motivated to review new therapies, and payers will reimburse new alternatives.

 

Multiple conditions can benefit from Bexson's ketamine platform

Numerous ICD-10 pain conditions would benefit from a ketamine delivery system capable of controlled, low dose infusions outside the clinic or hospital. Research shows ketamine can treat the following conditions: 

  • Post Laminectomy Syndrome & Failed Back Syndrome

  • Acute Post-Operative Pain

  • Acute and Chronic Migraine

  • Neuropathic Pain from Spinal Cord Injury

  • Fibromyalgia & Diffuse Connective Tissue Disease

  • Cervical Spine Trauma

  • Pain due to Nerve Injury

  • Chronic and Traumatic Neuropathy

  • Ischemic Limb Pain

  • Mechanical Allodynia

  • Post Herpetic Neuralgia

  • Trigeminal Neuralgia